Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Durect reported a quarterly loss of $0.06 per share, matching the Zacks Consensus Estimate, and showing improvement from a loss of $0.27 per share a year ago, representing an earnings surprise of -200% [1] - The company posted revenues of $0.45 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 93.44%, and down from $2.67 million in the same quarter last year [2] - Over the last four quarters, Durect has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Performance - Durect shares have increased by approximately 13.1% since the beginning of the year, contrasting with a decline of -1.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.11 on $2 million in revenues, and for the current fiscal year, it is -$0.52 on $7.05 million in revenues [7] Industry Outlook - The Medical - Drugs industry, to which Durect belongs, is currently in the top 33% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Durect's stock performance [5][6]